Krystal Biotech, Inc. · NASDAQ:KRYS
Krystal Biotech — Q2 2024 Earnings Presentation
14 slides from Krystal Biotech's earnings presentation, Aug 5, 2024
Slide 1: Second Quarter 2024 Financial Results and Business Update
Second Quarter 2024 Financial Results and Business Update August 5, 2024 © Copyright 2024 Krystal Biotech, Inc. All rights reserved.
Slide 2: Forward Looking Statements and Disclosures
Forward Looking Statements and Disclosures This presentation, which includes the accompanying oral presentation, contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about future expectations, plans and prospects for Krystal Biotec
Slide 3: Another Standout Quarter for Krystal
Another Standout Quarter for Krystal ▪ Strong fundamentals continues to propel U.S. VYJUVEK launch ▪ Three clinical trial readouts before year end 2024 ▪ Process and infrastructure improvements at our 2 CGMP facilities ▪ Strong cash position and another profitable quarter Krystal | 3
Slide 4: Total Net VYJUVEK Revenue of $166.2M Since Launch in August 2023
Total Net VYJUVEK Revenue of $166.2M Since Launch in August 2023 VYJUVEK Net Revenue ($M) ▪ Net revenues up 55.3% over prior quarter which had been affected by onetime disruptions ▪ Total net VYJUVEK revenue since launch of $166.2M $70.3 ▪ Gross margins of 91% in 2Q $42.1 $45.3 ▪ Gross-to-net adjust
Slide 5: Broad Access and Approvals Across DEB Population Driving Growth
Broad Access and Approvals Across DEB Population Driving Growth Reimbursement Approval Splits 97% By Commercial Medicaid Other Payer 46% 41% 12% Percentage of Covered Lives under Commercial and Medicaid Plans with Positive Access By DEB RDEB DDEB Subtype 78% 22% Over 400 Reimbursement Approvals To D
Slide 6: Home Dosing and High Compliance Holding Strong
Home Dosing and High Compliance Holding Strong VYJUVEK Site of Care (July 2024) 4% Patient Compliance (Through 2Q 2024) Home Treatment In Office Treatment 90% 96% - VYJUVEK Patient Ambassador Krystal | 6
Slide 7: Krystal's Integrated Commercial Strategy is Driving Awareness and Penetration
Krystal’s Integrated Commercial Strategy is Driving Awareness and Penetration of the U.S. DEB Patient Pool 1,200 3,000 Identified U.S. DEB Estimated U.S. Patients at Launch DEB Patients ✓ Claims Monitoring and Alerts ✓ Healthcare Professional Education ✓ Patient Outreach and Activation Krystal | 7
Slide 8: Raising Awareness and Activating Patients
Raising Awareness and Activating Patients Amplifying patient success stories s Recent publication authored by DEB key opinion leaders ▪ Webinar hosted virtually in May 2024 in provides practical guide for real-world use of VYJUVEK conjunction with EB Lifestyle ▪ Featured Krystal patient advocates sh
Slide 9: EU GMP Certification Granted and On Track for German Launch in 1H 2025
EU GMP Certification Granted and On Track for German Launch in 1H 2025 Europe ▪ Marketing authorization application validated in November 2023 2024 ▪ EMA manufacturing facility inspections completed in 2025 February 2024 and GMP certification received in May 2024 Europe ▪ On track for 2H 2024 decisi
Slide 10: Japan OLE Study Results Mirrored VYJUVEK Phase 3
Japan OLE Study Results Mirrored VYJUVEK Phase 3 Japan OLE Study ▪ Multicenter, open-label extension study in Japanese subjects with DEB Summary of Primary Wound Assessments ▪ The primary objective was to evaluate wound healing Per Protocol Population at 6 months, defined as complete closure of prim
Slide 11: Progressing Towards Multiple Clinical Readouts Starting Later This Year
Progressing Towards Multiple Clinical Readouts Starting Later This Year Three clinical readouts expected in 2H 2024 With more clinical data coming in 2025 ✓ KB301 for aesthetic indications – 3Q 2024 Ophthalmic B-VEC for ocular DEB complications ▪ Cohorts 3 and 4 in Phase 1 PEARL-1 fully enrolled ▪ N
Slide 12: Second Quarter 2024 Financial Highlights
Second Quarter 2024 Financial Highlights Cash and investments: $628.9 million as of June 30, 2024 Three Months Ended June 30 ($ in millions; except per share data) 2024 2023 Product revenue, net $70.3M - Cost of goods sold $6.0M - R&D expense $15.6M $12.1M SG&A expense $27.6M $25.9M Stock-based comp
Slide 13: Building Out a Portfolio of Redosable Genetic Medicines
Building Out a Portfolio of Redosable Genetic Medicines Indication Payload Preclinical Phase 1/2 Phase 3 Commercial Marketed Dystrophic epidermolysis bullosa (DEB) COL7A1 FDA Approved May 2023 in the U.S. KB105 Autosomal recessive congenital ichthyosis (ARCI) TGM1 KB104 Netherton syndrome SPINK5 Der
Slide 14: Developing Genetic Medicines to Treat Diseases with High Unmet Medical Needs
Developing Genetic Medicines to Treat Diseases with High Unmet Medical Needs © Copyright 2024 Krystal Biotech, Inc. All rights reserved.